Prescribing services for drug misuse. by unknown
Effective drug treatment involves a spectrum of care – from
counselling and detoxification, to prescribed medication and aftercare –
depending on the needs of a particular client. Prescribing medication
is an important element of many drug treatment programmes.
The National Treatment Agency (NTA) established a prescribing
expert group to advise the Agency on its approach and work
programme on prescribing. The group consists of substance misuse
specialists, general practitioners, psychiatrists, nurses and treatment
service users. This briefing has been developed by the group and
lead authors are identified for each section.
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This briefing outlines the key findings and recommendations of the NTA’s expert
prescribing group on:
• The evidence base for the pharmacological treatment of drug misuse
• Recommended guiding principles of an effective prescribing regime
• Recommended components of an effective prescribing service.
This briefing does not replace existing clinical guidelines (Department of 
Health, 1999). It has been produced to complement the existing guidelines and
the new service framework for drug treatment – Models of care (NTA, 2002).
Research into practice briefings are also available on line at www.nta.nhs.uk
Pharmacological treatment for
drug misusers: review of the
evidence base
Lead author: Dr Jenny Keen, Clinical Director, Primary Care Specialist Clinic for Drug Dependence,
North Sheffield Primary Care Trust and Clinical Research Fellow and Clinical Lecturer, Institute of
General Practice and Primary Care, University of Sheffield
In order to commission the best possible prescribing services for drug users, commissioning should be
based, as far as possible, on available evidence as to which treatments are effective (1,2,3). There are
recognised difficulties in developing a comprehensive and up-to-date evidence base for all forms of
treatment for drug misuse, but the aim of this briefing is to demonstrate what evidence is currently
available and to point out where gaps exist.
Summary
Some pharmacological treatments should be available to treat drug misuse on the basis of their strong
evidence base (e.g. methadone and buprenorphine). Others should be available because of the
importance or severity of the condition which they treat, even if their overall effectiveness is restricted to
some groups of patients. This category includes drugs such as lofexidine and naltrexone whose
relatively lower effectiveness may be due at least in part to the more stringent criteria imposed upon
them in measuring outcomes. There can, however, be no doubt regarding the strength of the evidence
base for oral methadone maintenance treatment. 
There is a further category of drugs for whose effectiveness very little evidence exists and where there
may be some contrary evidence suggesting that they should be used with caution: this group includes
dihydrocodeine and the benzodiazepines. Whilst these drugs may have some place in the
pharmacological treatment of drug dependence, they should be used with particular caution.
Oral methadone maintenance treatment
The best evidence for pharmacological treatments in the drugs field is for oral methadone which has
been shown to provide major harm minimisation outcomes in a variety of different settings over a
number of years (4,5,6). Against the reasonable assertion that oral methadone has not really been
tested in the modern British primary care setting (7,8) can be set a growing body of published
outcomes in this setting (9,10,11). The evidence as it stands suggests that: higher doses are better than
lower doses at retaining patients in treatment and optimising outcomes (12,13,14); enforced reduction in
oral methadone dose (as opposed to maintenance) is ineffective (15,16); and oral methadone treatment
accompanied by some form of non-prescribing intervention is probably more effective than methadone
alone (17). In view of the strength of the evidence for oral methadone treatment in reducing mortality
(18), reducing injecting behaviour (19) and preventing people from being forced to commit crimes in
order to obtain drugs (6), it seems essential that every area should offer accessible oral methadone
maintenance treatment for those who require this as a harm minimisation intervention. Treatment
provided in primary care will be appropriate for many patients.
Other maintenance treatments
There is a growing body of evidence for the efficacy of buprenorphine in the treatment of opioid
dependence (20,21,22). The level of evidence does not suggest that buprenorphine should replace
methadone as a substitution treatment, but rather that burprenorphine should now be considered an
evidence-based addition to the range of pharmacological maintenance treatments. Much of the
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emerging evidence derives from other European countries and the evidence for efficacy of this
treatment in Great Britain is very limited and based on very few studies.
Dihydrocodeine is not generally considered to be an appropriate medication for long term maintenance
(3,7) because there is a lack of evidence for its effectiveness, there are a number of practical problems
in dispensing it (tablet form, not eligible for controlled drug scripts etc) and the fact that it is not
licensed for this indication.
Injectable methadone has been found to compare favourably with oral methadone on a range of
treatment outcomes but has not been demonstrated to have better results than the oral formulation,
although there is some suggestion that certain subgroups of patients may benefit differentially from the
injectable form (23). Injectable diamorphine (heroin) has also been used for maintenance in some
specialist settings (see below).
Detoxification treatments
The evidence for success in detoxification treatments is far less compelling than the evidence for harm
minimisation maintenance interventions, and this may be in part because the aim of abstinence is
correspondingly harder to achieve. There is some evidence for the effectiveness of lofexidine (24,25),
although the Cochrane review (26) concluded that whilst clonidine and lofexidine had similar efficacy to
methadone when used for detoxification over a ten-day period, participants in fact stayed in treatment
longer with methadone and experienced fewer adverse effects. Lofexidine is considered by many
clinicians to be most suitable for patients using up to 50mg methadone or less than 1g heroin daily, for
those with shorter drug histories, and for non-polydrug users. Methadone as an agent for detoxification
is problematic for a number of reasons including its relative addictiveness and long duration of action
(7) but it remains a pragmatic choice in many cases where reduction and maintenance may have
become blurred. Buprenorphine on the other hand may overcome some of the problems of methadone
for detoxification, including a milder abstinence syndrome on withdrawal from the drug, and appears to
be as effective as methadone in detoxification from heroin (27,28). Dihydrocodeine has in the past been
used by practitioners for detoxification and there is some evidence for its efficacy (29) but its
advantages may well be superseded by those of buprenorphine (7).
In view of the above evidence, the expert group concluded that lofexidine, methadone and
buprenorphine should all have a place in the group of pharmacological therapies used for
detoxification. There are a number of newer approaches to detoxification such as rapid detoxification
under sedation or anaesthetic (30,31,32,33) and whilst these are not yet generally available or widely
researched and for this reason remain controversial (35,36,37), the evidence for their effectiveness
should be kept under review.
Pharmacological treatments for stimulant use
A number of Cochrane reviews show that current evidence does not support the use of dopamine
agonists, carbamazepine or antidepressants, with the possible exception of short-term fluoxetine
(38,39,40,41). Seivewright (7) has also reviewed the evidence for pharmacological treatments for
stimulant users and has concluded “there are precious few effective pharmacological treatment
options”. There is, however, an important and large group of patients who need to be attracted into
treatment in order to access harm minimisation and for specific treatment for their drug use. Harm
minimisation for stimulant users, and crack users in particular, is not well developed, and local areas
may want to look at the further development (and evaluation) of such initiatives. Especially in view of the
potential severity of the withdrawal syndrome from these drugs, appropriate interventions for users of
stimulants such as crack cocaine and amphetamine should be available in all areas in spite of the
relative lack of evidence for the effectiveness of pharmacological treatments for this group. Such
treatments may, in a specialist setting, include interventions such as dextroamphetamine (42) and
amelioration of withdrawal symptoms with selective serotonin re-uptake inhibitors (SSRIs) such as
fluoxetine and/or short term benzodiazepines. In some cases, inpatient treatment may be necessary.
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Whilst the evidence base for individual pharmacological treatments is still highly unsatisfactory, results
from the National Treatment Outcome Research Study (NTORS) suggests that stimulant users who use
stimulants both as a primary drug and as part of a range of polydrug use do, nevertheless, benefit from
a range of treatment interventions, especially in rehabilitation services (43).
Benzodiazepines
Benzodiazepines are frequently used by drug misusers as a secondary drug, either to enhance the
effect of the primary drug or to ameliorate withdrawal effects. They have strong addictive potential, the
withdrawal syndrome can be dangerous, and they are known to be a major contributor to deaths from
drug misuse. Whilst there is no evidence to support their use for maintenance treatment (3), in view of
the major role which they occupy in the field of drug misuse, services must be able to accommodate
and treat benzodiazepine use and to prescribe benzodiazepines where appropriate (3) and within their
licence. In general this will mean using benzodiazepines primarily for people withdrawing from
benzodiazepine dependence.  
Relapse prevention
Reviews of the effectiveness of naltrexone, the most commonly used pharmacological treatment in
relapse prevention, have not been entirely favourable (38) but effectiveness has been demonstrated by
some studies, particularly for highly motivated individuals. The Cochrane review of naltrexone
maintenance treatment for opioid dependence (39) concludes that the available trials do not allow a final
evaluation of naltrexone maintenance treatment yet. Studies of naltrexone inevitably suffer from the high
rate of relapse associated with opiate dependence and poor outcomes may reflect inappropriate
outcome criteria (40). Combined use of naltrexone and psychosocial therapy has proved to be more
effective than either therapy alone in improving post treatment outcomes (41).
Whilst the evidence for naltrexone does not suggest that it will be suitable for every patient, it should
nevertheless be available as a treatment option to those who can benefit, not least because of the
supreme importance of avoiding relapse.  
Specialist prescribing opiate maintenance options
There is some emerging evidence for the effectiveness of prescribing intravenous diamorphine for
certain groups of patients (42). Whilst there is little research on the effectiveness of injectable
methadone, there is considerable agreement amongst many clinicians that this is an important specialist
prescribing option for some patients (4). Other specialised drug regimens are similarly uninvestigated
but may have a place in the range of treatment options available to the specialist. However,
consideration of safe dispensing and avoidance of diversion are essential.
Recommendations
Further research and systematic reviews should be carried out in UK settings especially in the following
areas: 
• effectiveness of treatment in primary care settings
• treatment of stimulant use including harm minimisation
• use of buprenorphine in UK settings
• effectiveness of lofexidine and naltrexone
• treatment of benzodiazepine dependence
• use of rapid detoxification treatments.
Commissioners, planners and providers of drugs services should use the evidence as outlined in this
paper when making decisions regarding the essential components of a drugs service and how these
should be delivered.
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Guiding principles on prescribing
Lead author: Bill Nelles, Methadone Alliance
Careful and appropriate prescribing has been shown to reduce the risks to individuals from illicit drug
use. Interventions should prioritise reducing the harm of illicit drug use by offering appropriate and
individualised interventions in a safe and effective manner. There is appropriate guidance on this in the
Drug misuse and dependence: guidelines on clinical management (Department of Health, 1999). 
Prescribing should be tailored to the needs of each individual. The effectiveness of prescribing
treatments is further increased when services such as psychological and social support are also
provided as appropriate.
Prescribing practices should reflect the evidence base that currently exists. The existing evidence base
should also be expanded through the evaluation and research of appropriate interventions – particularly
those that have shown success in other areas.   
Similar models of prescribing must be available to people in all parts of the country. Each area has a
responsibility to ensure all patients can access a comprehensive range of interventions (see service
framework outlined in Models of care, NTA, 2002).  
Ideally, doctors and patients are partners in care. When prescribing is initiated, there should be broad
agreement between doctor and patient on the short and longer term goals of such treatment. Any
reduction programme should be agreed with the patient, and undertaken with their active consent.
Enforced reduction of methadone is rarely effective, particularly in people with a longstanding addiction
to opiates.
Prescribing components of a
drug treatment service 
Lead author: Dr Emily Finch, Consultant Psychiatrist, Maudsley Community Addictions Services,
South London and Maudsley NHS Trust.
The prescribing components outlined here are designed to complement work already developed in the
new service framework for drug treatment - Models of care (NTA, 2002). Prescribing regimens will follow
general principles set out in Drug misuse and dependence: guidelines on clinical management
(Department of Health, 1999). Importantly, prescribing is only one part of an overall treatment package.
The guidance given in Developing an integrated model of care for drug treatment (Department of
Health, 2001) is a fuller discussion of the nature of a treatment episode. 
Essential components 
The following components must be included in a prescribing service:
• Assessment of prescribing needs.
• Safe flexible systems of assessment of appropriate dose, taking into account the risk of overdose
and needs of the patient.
• Access to specialist community-based prescribing within six weeks for 2002/03 and three weeks 
for 2003/04 onwards. Access to GP community-based prescribing within four weeks for 2002/03 
and two weeks from 2003/04 onwards. Access to inpatient detoxification within four weeks for 
2002/03 and two weeks from 2003/04 onwards.
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• The duration of treatment should be:
• Short term (up to 21 days) outpatient detoxification with lofexidine, buprenorphine or other
pharmacological support
• Medium term (1 to 6 months) detoxification with methadone or buprenorphine
• Inpatient detoxification with various pharmacological options available
• Longer term or maintenance treatment with oral methadone or buprenorphine.
• Supervised dispensing and daily dispensing for:
• the initial stages of treatment  
• for clients who fail to reduce illicit drug use or 
• those whose lifestyles remain chaotic.
• Detoxification treatment for individuals with concurrent alcohol dependence.
• Urine or saliva testing to assist in assessing dependence initially and to monitor that the drug 
prescribed is being taken. 
• Objectives and outcome goals should be built into a prescribing episode. These objectives can 
be harm reduction or abstinence based ones (e.g. cessation of injecting or improvement of 
physical health). The prescription must be reviewed regularly by the prescriber and the goals 
must be monitored.
• Adequately and regularly trained and supported prescribers. 
• Prescribing options for special groups (e.g. pregnant drug users, young people under 21 and 
clients in contact with criminal justice services).
• Appropriate care co-ordination to ensure psycho-social and other elements of treatment 
are provided. 
• Adequate doses for those on oral methadone maintenance (e.g. on average 60–120mg daily).
Desirable components
It is desirable that a prescribing service should have the following components:
• Access to new treatment options, as they become available (e.g. emerging treatments for 
cocaine addiction).
• Substitute prescribing for concurrent benzodiazepine addiction in polysubstance abusers.
• High dose methadone prescribing (i.e. above 120mg).
• Opiate antagonist prescribing (e.g. naltrexone and pre- prescribing challenge). 
• Inpatient stabilisation programmes.
• Specialist prescribing options (e.g. injectable methadone, injectable diamorphine and morphine
sulphate).*
• Prescribing for stimulant users (e.g. antidepressants for post cocaine depression and possibly
dexamphetamine prescribing for amphetamine users).** 
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* Research should be commissioned to clarify the role for these options. Evidence based guidance is being developed 
by the NTA on injectable heroin and methadone.
**Further research will soon be available which may provide more evidence on the effectiveness of dexamphetamine 
prescribing for amphetamine users.
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